Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

SKYSCRAPER 5 : A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Multiple treatment types,Surgical,Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II study is evaluating safety and feasibility of combination immunotherapy (atezolizumab + tiragolumab) alone, or in combination with platinum-based chemotherapy, as treatment prior to surgery in people with previously untreated locally advanced non-small cell lung cancer.
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy and surgical trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible participants will be allocated to one of two experimental arms. Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A, and will receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgery to remove the cancer, and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles, at the discretion of the investigator. Participants with any PD-L1 expression level will be enrolled in Cohort B, and will receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgery to remove the cancer, and adjuvant atezolizumab plus tiragolumab for 16 cycles. In both Cohorts, Atezolizumab will be given at a dose of 1200mg administered via intravenous infusion on Day 1 of each 21-day cycle, and Tiragolumab will be given at a dose of 600mg administered via intravenous infusion on Day 1 of each 21-day cycle. In both Cohorts, chemotherapy may include cisplatin/carboplatin + pemetrexed (for non-squamous only); cisplatin/carboplatin + gemcitabine (for squamous only); or carboplatin + paclitaxel.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Rachel McMenamin
PCCTU.MoncB@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next